首页> 美国卫生研究院文献>The Canadian Child and Adolescent Psychiatry Review >Clonidine as a Treatment of Behavioural Disturbances in Autism Spectrum Disorder: A Systematic Literature Review
【2h】

Clonidine as a Treatment of Behavioural Disturbances in Autism Spectrum Disorder: A Systematic Literature Review

机译:可乐定作为自闭症谱系障碍行为障碍的治疗方法:系统文献综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Agitation and aggression are commonly cited reasons for psychiatry consultation for individuals diagnosed with autism spectrum disorder (ASD). While risperidone and aripiprazole do not carry Health Canada approval for management of ASD-associated irritability, both are used for this indication but are not universally effective and carry substantial risk of adverse effects. This necessitates use of off-label medications to assist in management of behavioral dysregulation. Clonidine, an alpha-2 receptor agonist, is approved in Canada for treatment of hypertension. The evidence base also supports its use for attention deficit/hyperactivity disorder (ADHD) and for tics in Tourette’s disorder. This review focuses on examining the literature regarding clonidine as a treatment of challenging behaviours in the ASD population.
机译:躁动和攻击性是被诊断出患有自闭症谱系障碍(ASD)的个人进行精神科咨询的原因。尽管利培酮和阿立哌唑未获得加拿大卫生部批准用于治疗与ASD相关的烦躁不安,但两者均用于该适应症,但并不普遍有效,并且具有产生不良反应的巨大风险。这就需要使用标签外的药物来协助应对行为失调。可乐定是一种α-2受体激动剂,已在加拿大批准用于治疗高血压。证据基础还支持将其用于注意力缺陷/多动障碍(ADHD)和抽动秽语障碍症。这篇综述着重于研究有关可乐定作为ASD人群挑战性行为治疗的文献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号